Summary: No, psychedelics and hallucinogens are not legal now. Recent changes in mental health policy at the federal level have changed the research status of specific medications considered psychedelics and/or hallucinogens, but not their legal status.
Key Points:
- Psychedelic psychotherapy and mental health treatment with psychedelic or hallucinogenic medications show promising results in initial research.
- Psychedelics and hallucinogens relieve symptoms through different mechanisms than traditional psychiatric medications
- They may also relieve symptoms more quickly, and for a longer period, than traditional psychiatric medications.
New Federal Policy on Psychedelics for Mental Health
On April 26th 2026 the White House released a new directive called “Accelerating Treatments for Serious Mental Illness” that outlines a significant shift in public policy toward mental health research in general, and toward research into medications considered psychedelics that often have hallucinogenic properties. Here’s the operative language in the order:
“Individuals suffering from major depressive disorder and substance abuse disorder can relapse or not fully respond to standard medical and psychiatric therapies. Innovative methods are needed to find long-term solutions. Psychedelic drugs show potential in clinical studies to address serious mental illness.
[We will] accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs that could save lives and reverse the crisis of serious mental illness in America.”
The order, in essence, fast-tracks research for specific drugs that meet pre-established clinical and research criteria. The order provides funding and a voucher program to speed trials of breakthrough therapies, and exceptions when medications in those therapies appear as Schedule I controlled substances.
To be clear, this is a separate order than the order directing federal agencies to reclassify marijuana from a Schedule I, strictly controlled substance like heroin, to a Schedule III, less strictly controlled substance, such as cough syrup with codeine, hormones for hormone therapy, and anabolic steroids.
This order targets three medications for use in treatment for mental health or substance use disorders:
- Psilocybin
- Ibogaine
- Methylone (MDMA)
Federal policy changes will prioritize research for these medications, but nothing in this order makes psychedelics and hallucinogens legal or more accessible for personal use or nonprescription medical use: these substances are still illegal for the general public.
How Can These Drugs Help Mental Health Treatment?
The order, and the medications it covers, focuses on treatment resistant mental health disorders including major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). It also directs funding toward substance use disorders, which have high relapse rates, making them – like MDD and PTSD – treatment resistant mental health disorders.
We’ll review the potential benefits of each medication now.
Psilocybin:
This is the active compound in the recreational psychedelic known as mushrooms or magic mushrooms. Psilocybin acts on brain areas associated with mood, emotion regulation, and cognitive processing. When activated, brain receptors in these areas promote neuroplasticity, i.e. the ability to adapt and change. Researchers predict that treatment with psilocybin can help reset the brain, thereby reducing or eliminating symptoms associated with depressive disorders.
Methylone:
This is a synthetic compound that mimics the action and effects of MDMA, commonly known as the recreational party drug, ecstasy. It has two primary effects: it behaves as an entactogen and a stimulant. This combined effect causes feeling of peace, connection, love, trust, openness, and overall decreases in fear and inhibition. Researchers predict that in this state of mind, patients with a history of trauma or PTSD will feel safe, secure, and willing to talk about past trauma and learn healthy ways of processing events that previously would have triggered panic attacks, physical discomfort, and severe psychological distress.
Ibogaine:
Ibogaine is an alkaloid derived from the Iboga shrub in Western Africa. It has strong hallucinogenic and psychedelic properties, with documented use in rituals and ceremonies since at least the 1700s. Early research shows ibogaine can be an effective adjunct treatment for people with opioid, cocaine, heroin, and alcohol addiction. Recent research indicates ibogaine may be effective in reducing symptoms for people with major depressive disorder (MDD), post-traumatic stress disorder (PTSD), phobias, and generalized anxiety disorder (GAD).
Future Directions: Clinical Data Needed for Psychedelics
All three of these drugs have potential. However, a significant number of questions related to safety and treatment protocols remain unanswered. That’s what this research effort is about: asking and answering these questions so we know whether these drugs will become viable options for mental health treatment for the general public, or remain as experimental, off-label treatments with the potential for both significant risk and reward.
When researchers publish the results of this new series of clinical trials, we’ll share the results here. We look forward to what they find: this is a promising thread of research that could offer real benefit and relief for patients with treatment resistant mental health disorders.
For a detailed assessment of ibogaine for people with PTSD, please read the following article on our blog:
Gianna Melendez
Jodie Dahl, CpHT